Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD06 in hepatocellular carcinoma after radical resection
NCT06088459Phase 1Recruiting
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NWRD06 in hepatocellular carcinoma (HCC), sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoints: Dose-limiting toxicity and Adverse Events at 12 weeks. Started Nov 2023; status: recruiting.
02
Drugs
NWRD06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06088459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088459.